title: Neuroprotective effect of resveratrol prophylaxis on experimental retinal ischemic injury.
abstract: The purpose of the present study was to investigate whether systemically administered resveratrol can protect against acute retinal ischemic reperfusion injury. Two groups of adult male Sprague Dawley rats (n = 6 per group) were used for this study. Resveratrol (30 mg/kg) or an equal volume of vehicle (30% Solutol HS 15 in 0.9% saline) was administered daily for 5 days via intraperitoneal injection. On the third day of treatment, retinal ischemic injury was induced by elevation of intraocular pressure for 45 min. Prior to resveratrol administration and one-week following ischemic insult, retinal function was measured by scotopic electroretinography (ERG). Retinas were harvested and morphologically analyzed one week after ischemic insult. ERG a- and b-wave amplitudes were significantly reduced following ischemic reperfusion injury. Resveratrol treatment attenuated ischemic-induced loss of retinal function. In control vehicle-treated rats, ischemic reperfusion injury elicited marked thinning of inner retinal layers. Resveratrol prophylactic treatment reduced ischemia-mediated thinning of the whole retina and in particular the inner retinal layers. Therefore, resveratrol may have therapeutic value for the management of retinal ischemic disorders.
authors.affiliation: Department of Ophthalmology, Loyola University Chicago, Maywood, IL 60153, USA.
authors.forename: Anita P
authors.initials: AP
authors.lastname: Vin
authors.forename: Hanbo
authors.initials: H
authors.lastname: Hu
authors.forename: Yougang
authors.initials: Y
authors.lastname: Zhai
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Von Zee
authors.forename: Andrew
authors.initials: A
authors.lastname: Logeman
authors.forename: Evan B
authors.initials: EB
authors.lastname: Stubbs
authors.forename: Jay I
authors.initials: JI
authors.lastname: Perlman
authors.forename: Ping
authors.initials: P
authors.lastname: Bu
mesh_terms: D000818:Animals; D019610:Cytoprotection; D004195:Disease Models, Animal; D004596:Electroretinography; D007274:Injections, Intraperitoneal; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D000077185:Resveratrol; D012160:Retina / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D012164:Retinal Diseases / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018696:Neuroprotective Agents; D013267:Stilbenes; D000077185:Resveratrol